Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.

作者： Thomas Aparicio , , Jaafar Bennouna , Karine Le Malicot , Valérie Boige

关键词:

摘要: Background Identifying patients with metastatic colorectal cancer who will have an early disease progression during induction chemotherapy (IC) and identifying may a chemotherapy-free interval (CFI) after IC are two major challenges. Methods A logistic model was used to identify factors associated short duration of the first CFI in 488 enrolled PRODIGE 9 trial. Independent were defined threshold 0.10. Results In multivariate analysis, baseline leukocytes >10 × 109/L (OR = 1.98 [1.02-3.8], p 0.04), stable or increasing CEA at 2 months 3.61 [1.68-7.75], 0.01) independent IC. Male gender 1.725 [0.92-3.325], 0.09) no tumour response evaluation 1.90 [0.96-3.76], 0.07) significantly CFI. The presence BRAF V600E mutation also 4.59 [0.95; 22.3], 0.058). Conclusion High leukocyte count lack decrease level progression, could be favour intensification. gender, CFI, considered for maintenance Clinical trial number NCT00952029.

参考文章(25)

Allan Andresson Lima Pereira, Juliana Florinda de Mendonça Rego, Rodrigo Ramela Munhoz, Paulo Marcelo Hoff, Andre Deeke Sasse, Rachel P. Riechelmann, The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials. Acta Oncologica. ,vol. 54, pp. 1737- 1746 ,(2015) , 10.3109/0284186X.2015.1044022

T. Aparicio, S. Lavau-Denes, J.M. Phelip, E. Maillard, J.L. Jouve, D. Gargot, M. Gasmi, C. Locher, X. Adhoute, P. Michel, F. Khemissa, T. Lecomte, J. Provençal, G. Breysacher, J.L. Legoux, C. Lepère, J. Charneau, J. Cretin, L. Chone, A. Azzedine, O. Bouché, I. Sobhani, L. Bedenne, E. Mitry, P. Amoyal, D. Auby, J.B. Bachet, M. Baconnier, R. Benoit, O. Berthelet, A. Bidault, C. Bineau, G. Bordes, N. Bouarioua, E. Boucher, O. Boulat, D. Cleau, P. Couzigou, E. Cuillerier, I. Cumin, B. Denis, F. Di Fiore, V. Derias, J. Ezenfis, R. Faroux, A. Gagnaire, G. Gatineau-Sailliant, B. Garcia, D. Genet, A. Gueye, P. Hammel, J.P. Lagasse, B. Landi, C. Lepage, C. Lobry, C. Lombard-Bohas, M. Mabro, R. Mackiewicz, J. Martin, X. Moncoucy, F. Morvan, M. Mozer, M. Pauwels, F. Petit-Laurent, P. Pouderoux, P. Prost, A.M. Queuniet, M. Ramdani, C. Rebischung, P. Rougier, M. Schnee, J.F. Seitz, L. Stefani, J. Taïeb, E. Terrebonne, P. Texereau, J. Thaury, D. Tougeron, A. Weber, F. Ricard, F. Bonnetain, F. Masskouri, C. Choine, F. Guiliani, G. Le Pessec, H. Fattouh, N. Le Provost, C. Girault, M. Schneider, Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02) Annals of Oncology. ,vol. 27, pp. 121- 127 ,(2012) , 10.1093/ANNONC/MDV491

Justin Guinney, Rodrigo Dienstmann, Xin Wang, Aurélien De Reynies, Andreas Schlicker, Charlotte Soneson, Laetitia Marisa, Paul Roepman, Gift Nyamundanda, Paolo Angelino, Brian M Bot, Jeffrey S Morris, Iris M Simon, Sarah Gerster, Evelyn Fessler, Felipe De Sousa E Melo, Edoardo Missiaglia, Hena Ramay, David Barras, Krisztian Homicsko, Dipen Maru, Ganiraju C Manyam, Bradley Broom, Valerie Boige, Beatriz Perez-Villamil, Ted Laderas, Ramon Salazar, Joe W Gray, Douglas Hanahan, Josep Tabernero, Rene Bernards, Stephen H Friend, Pierre Laurent-Puig, Jan Paul Medema, Anguraj Sadanandam, Lodewyk Wessels, Mauro Delorenzi, Scott Kopetz, Louis Vermeulen, Sabine Tejpar, None, The consensus molecular subtypes of colorectal cancer Nature Medicine. ,vol. 21, pp. 1350- 1356 ,(2015) , 10.1038/NM.3967

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4

Thomas Aparicio, Benjamin Linot, Karine Le Malicot, Olivier Bouché, Valérie Boige, Eric François, Francois Ghiringhelli, Jean-Louis Legoux, Meher Ben Abdelghani, Jean-Marc Phelip, Roger Faroux, Laetitia Dahan, Julien Taieb, Laurent Bedenne, FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 – FFCD 0802) Digestive and Liver Disease. ,vol. 47, pp. 271- 272 ,(2015) , 10.1016/J.DLD.2015.01.146

Scott Kopetz, George J. Chang, Michael J. Overman, Cathy Eng, Daniel J. Sargent, David W. Larson, Axel Grothey, Jean-Nicolas Vauthey, David M. Nagorney, Robert R. McWilliams, Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy Journal of Clinical Oncology. ,vol. 27, pp. 3677- 3683 ,(2009) , 10.1200/JCO.2008.20.5278

Christophe Tournigand, Andres Cervantes, Arie Figer, Gérard Lledo, Michel Flesch, Marc Buyse, Laurent Mineur, Elisabeth Carola, Pierre-Luc Etienne, Fernando Rivera, Isabel Chirivella, Nathalie Perez-Staub, Christophe Louvet, Thierry André, Isabelle Tabah-Fisch, Aimery de Gramont, OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study Journal of Clinical Oncology. ,vol. 24, pp. 394- 400 ,(2006) , 10.1200/JCO.2005.03.0106

R. Labianca, A. Sobrero, L. Isa, E. Cortesi, S. Barni, D. Nicolella, M. Aglietta, S. Lonardi, D. Corsi, D. Turci, G.D. Beretta, G. Fornarini, E. Dapretto, I. Floriani, A. Zaniboni, Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial Annals of Oncology. ,vol. 22, pp. 1236- 1242 ,(2011) , 10.1093/ANNONC/MDQ580

C.-H. Köhne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, E. Aranda, W. Scheithauer, P. Rougier, M. Palmer, J. Wils, B. Baron, F. Pignatti, P. Schöffski, S. Micheel, H. Hecker, Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Annals of Oncology. ,vol. 13, pp. 308- 317 ,(2002) , 10.1093/ANNONC/MDF034

10.

Richard A Adams, Angela M Meade, Matthew T Seymour, Richard H Wilson, Ayman Madi, David Fisher, Sarah L Kenny, Edward Kay, Elizabeth Hodgkinson, Malcolm Pope, Penny Rogers, Harpreet Wasan, Stephen Falk, Simon Gollins, Tamas Hickish, Eric M Bessell, David Propper, M John Kennedy, Richard Kaplan, Timothy S Maughan, Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet Oncology. ,vol. 12, pp. 642- 653 ,(2011) , 10.1016/S1470-2045(11)70102-4

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.

来源期刊

我的账户

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.

来源期刊

相似文章 3

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.

Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer.

我的账户